{"id":66343,"date":"2026-05-26T14:59:38","date_gmt":"2026-05-26T06:59:38","guid":{"rendered":"https:\/\/flcube.com\/?p=66343"},"modified":"2026-05-26T14:59:39","modified_gmt":"2026-05-26T06:59:39","slug":"hotgen-biotech-secures-nmpa-clinical-filing-acceptance-for-sgc001-monoclonal-antibody-in-severe-acute-pancreatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66343","title":{"rendered":"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hotgen Biotech Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688068:SHA\">SHA: 688068<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has <strong>accepted for review<\/strong> its clinical trial application for <strong>SGC001<\/strong>, a <strong>monoclonal antibody drug for emergency use<\/strong>, for the treatment of <strong>severe acute pancreatitis<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Filing Status<\/strong><\/td><td>Clinical trial application accepted for review<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SGC001 \u2013 monoclonal antibody for emergency use<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Severe acute pancreatitis<\/td><\/tr><tr><td><strong>Previous Indications<\/strong><\/td><td>Acute myocardial infarction (AMI) \u2013 approved for clinical trials in China and US<\/td><\/tr><tr><td><strong>US Regulatory Status<\/strong><\/td><td><strong>Fast Track designation<\/strong> granted by FDA (March 2025)<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>May 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-development-history\" class=\"wp-block-heading\">Drug Profile &amp; Development History<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Monoclonal antibody<\/strong> formulated for <strong>emergency administration<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Area Expansion:<\/strong> Originally developed for <strong>acute myocardial infarction (AMI)<\/strong>, now expanding to <strong>severe acute pancreatitis<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Recognition:<\/strong> <strong>FDA Fast Track designation<\/strong> validates significant unmet medical need and therapeutic potential<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Active clinical programs in both <strong>China and United States<\/strong> demonstrate international strategy<\/li>\n\n\n\n<li><strong>Emergency Use Focus:<\/strong> Designed for rapid administration in critical care settings where time is crucial<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-unmet-medical-need\" class=\"wp-block-heading\">Market Opportunity &amp; Unmet Medical Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Market Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Severe Acute Pancreatitis<\/strong><\/td><td>&#8211; Estimated 200,000-300,000 annual cases in China<br>&#8211; <strong>No approved disease-modifying therapies<\/strong><br>&#8211; High mortality rate (15-30% in severe cases)<br>&#8211; Current treatment limited to supportive care<\/td><\/tr><tr><td><strong>Acute Myocardial Infarction<\/strong><\/td><td>&#8211; Massive global market with established standard of care<br>&#8211; Fast Track designation indicates potential superiority over existing treatments<br>&#8211; Emergency use setting enables premium pricing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The expansion into severe acute pancreatitis represents a strategic diversification while leveraging the same emergency-use monoclonal antibody platform.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-strategic-positioning\" class=\"wp-block-heading\">Competitive Landscape &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Potential:<\/strong> No approved monoclonal antibodies specifically for severe acute pancreatitis<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success in AMI indication de-risks development for pancreatitis<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> Concurrent NMPA and FDA engagement accelerates global development timeline<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> Emergency-use products benefit from hospital-focused sales model already established for AMI indication<\/li>\n\n\n\n<li><strong>Pricing Power:<\/strong> Orphan-like status in pancreatitis indication supports premium pricing strategy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-strategy-amp-timeline-outlook\" class=\"wp-block-heading\">Development Strategy &amp; Timeline Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Expected Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>NMPA Clinical Approval<\/strong><\/td><td>Q3-Q4 2026<\/td><\/tr><tr><td><strong>Phase I\/II Initiation (Pancreatitis)<\/strong><\/td><td>2027<\/td><\/tr><tr><td><strong>Global Phase III (AMI)<\/strong><\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Potential NDA Submissions<\/strong><\/td><td>2028-2029 (depending on indication)<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>2029-2030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The dual-indication strategy provides multiple pathways to market while sharing development costs and regulatory risk across therapeutic areas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations for SGC001. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688068_20260526_U5DD.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688068_20260526_U5DD.\"><\/object><a id=\"wp-block-file--media-6049d006-ae4a-47e2-b68f-8bfb71905c01\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688068_20260526_U5DD.pdf\">688068_20260526_U5DD<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688068_20260526_U5DD.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6049d006-ae4a-47e2-b68f-8bfb71905c01\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[420,1205],"class_list":["post-66343","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-hotgen-biotech","tag-sha-688068"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for SGC001, a monoclonal antibody drug for emergency use, for the treatment of severe acute pancreatitis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66343\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis\" \/>\n<meta property=\"og:description\" content=\"Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for SGC001, a monoclonal antibody drug for emergency use, for the treatment of severe acute pancreatitis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66343\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T06:59:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-26T06:59:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66343#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66343\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis\",\"datePublished\":\"2026-05-26T06:59:38+00:00\",\"dateModified\":\"2026-05-26T06:59:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66343\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Hotgen Biotech\",\"SHA: 688068\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66343#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66343\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66343\",\"name\":\"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-26T06:59:38+00:00\",\"dateModified\":\"2026-05-26T06:59:39+00:00\",\"description\":\"Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for SGC001, a monoclonal antibody drug for emergency use, for the treatment of severe acute pancreatitis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66343#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66343\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66343#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis - Insight, China&#039;s Pharmaceutical Industry","description":"Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for SGC001, a monoclonal antibody drug for emergency use, for the treatment of severe acute pancreatitis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66343","og_locale":"en_US","og_type":"article","og_title":"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis","og_description":"Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for SGC001, a monoclonal antibody drug for emergency use, for the treatment of severe acute pancreatitis.","og_url":"https:\/\/flcube.com\/?p=66343","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-26T06:59:38+00:00","article_modified_time":"2026-05-26T06:59:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66343#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66343"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis","datePublished":"2026-05-26T06:59:38+00:00","dateModified":"2026-05-26T06:59:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66343"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Hotgen Biotech","SHA: 688068"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66343#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66343","url":"https:\/\/flcube.com\/?p=66343","name":"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-26T06:59:38+00:00","dateModified":"2026-05-26T06:59:39+00:00","description":"Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial application for SGC001, a monoclonal antibody drug for emergency use, for the treatment of severe acute pancreatitis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66343#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66343"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66343#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66343"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66343\/revisions"}],"predecessor-version":[{"id":66345,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66343\/revisions\/66345"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}